Category: Partners

  • LASIK in Northern Colorado: Personalized Vision Correction from a National Leader in Refractive Surgery

    LASIK in Northern Colorado: Personalized Vision Correction from a National Leader in Refractive Surgery

    For those considering LASIK in Northern Colorado, Vance Thompson Vision offers nationally recognized care delivered by an experienced surgical team using the most advanced laser technology available today. With a reputation built on research, innovation, and personalized outcomes, the Northern Colorado clinic provides patients with clear answers, a seamless experience, and life-changing visual results — all within a welcoming and professional setting.

    LASIK (Laser-Assisted In Situ Keratomileusis) is the most well-known laser vision correction procedure, used to treat refractive errors such as nearsightedness, farsightedness, and astigmatism. At Vance Thompson Vision, LASIK is fully customized for each patient through the use of wavefront-guided imaging, which maps the eye in extreme detail. This personalized approach allows the surgeon to target the exact areas of the cornea that need reshaping, improving visual clarity and reducing issues like halos, glare, and night vision difficulty.

    Patients in Northern Colorado benefit from the same advanced LASIK technology and techniques used across Vance Thompson Vision’s entire network, including femtosecond laser flap creation and precise excimer laser reshaping. The entire procedure typically takes about 20 minutes, and most patients return to work and daily activities the very next day. Initial follow-up care begins just one day after surgery, and the vast majority of patients report dramatic improvement in their vision within hours of the procedure.

    The Northern Colorado team is composed of board-certified, fellowship-trained surgeons and a skilled clinical staff that works closely with patients through every step — from the initial consultation and testing to surgery and long-term follow-up. The clinic’s approach to care emphasizes education and transparency, ensuring that patients feel informed and confident in their decisions.

    LASIK may be the right solution for many people, but it isn’t the only option. As a comprehensive refractive surgery center, Vance Thompson Vision also offers PRK (Photorefractive Keratectomy), ICL (Implantable Collamer Lens), and RLE (Refractive Lens Exchange) for patients who are not ideal LASIK candidates. Thin corneas, certain prescriptions, or other eye conditions may make an alternative procedure a better fit, and the Northern Colorado team has the training and technology to provide those alternatives with the same level of safety and success.

    The clinic’s complimentary LASIK consultations are thorough and data-driven. Each consultation includes dilation, corneal mapping, and dry eye testing to determine candidacy. Patients who wear contact lenses will be advised to stop wearing them prior to their evaluation, as lenses can temporarily alter the shape of the cornea and impact the accuracy of measurements. These extra steps help ensure precise treatment planning and the best possible visual outcomes.

    During the LASIK procedure itself, numbing drops are used to keep patients comfortable. A device gently holds the eyelids open, and a mild sedative may be offered to help ease anxiety. Patients remain awake and are guided throughout the process, which involves creating a flap in the cornea, reshaping the underlying tissue with a cool laser, and repositioning the flap to heal naturally. Most patients begin noticing visual improvement before they leave the office.

    Recovery is typically fast and straightforward. Temporary side effects such as light sensitivity, tearing, or mild discomfort may occur for a few hours after surgery. Patients are advised to avoid eye makeup, swimming, and rubbing their eyes for the first few days. Artificial tears may be recommended to support healing and comfort. A follow-up appointment is scheduled the next day, and additional post-operative visits ensure long-term visual success.

    Cost transparency is a key part of the patient experience at Vance Thompson Vision in Northern Colorado. While LASIK is not generally covered by insurance, the practice provides clear pricing that includes the procedure, follow-up care, eye drops, and any necessary fine-tuning for up to two years. Flexible financing options are also available to make vision correction more accessible, and dedicated counselors are available to walk patients through those choices.

    As a practice that contributed to the original FDA-monitored LASIK trials, Vance Thompson Vision has long been a leader in setting the standard for modern laser vision correction. The Northern Colorado clinic continues that legacy, providing patients with the same level of innovation, surgical skill, and attentive care that define the Vance Thompson Vision brand across all its locations.

    The impact of LASIK often extends well beyond improved vision. Patients describe the sense of freedom that comes from waking up and seeing clearly without glasses, the convenience of no longer relying on contacts, and the confidence of engaging in work, hobbies, and sports without visual barriers. For many, LASIK represents a turning point — one that brings their daily routines and long-term goals into clearer focus.

    Patients throughout Northern Colorado who are interested in LASIK or other refractive procedures are encouraged to schedule a complimentary consultation to determine their options. Vance Thompson Vision welcomes individuals at all stages of the decision-making process, whether they’re actively preparing for surgery or simply gathering information.

    Reporters and health writers seeking expert commentary on LASIK, custom laser technology, or trends in refractive surgery are invited to contact the Northern Colorado clinic for interviews and additional insights.

    The post LASIK in Northern Colorado: Personalized Vision Correction from a National Leader in Refractive Surgery appeared first on DA80 Hub.

  • MATRIXX Software Extends Monetization Partnership With StarHub

    MATRIXX Software Extends Monetization Partnership With StarHub

    Cloud native charging architecture will transform consumer and enterprise operations

    FOSTER CITY, CA / ACCESS Newswire / July 28, 2025 / MATRIXX Software, a global leader in monetization solutions, today announced a five-year extension of its partnership with StarHub, a leading Singapore-based telecommunications company. Initially deployed to support the rapid launch of giga!, StarHub’s all-digital offering, StarHub is further leveraging MATRIXX to support their main brand offerings for both consumer and enterprise customers.

    “StarHub is modernizing from the inside out, driving growth in our consumer business through smarter cross-product bundling and a multi-brand, multi-segment strategy that creates meaningful value,” said Adam Seyer, chief information officer at StarHub. “At the same time, we are scaling modern digital infrastructure across Singapore and the region to support our enterprise customers’ ambitions. By extending our collaboration with MATRIXX, we are equipping ourselves to deliver simpler, faster, and more seamless digital experiences that cater to our customers’ evolving needs.”

    Building on the success of its initial rollout, StarHub continues to leverage MATRIXX’s cloud native monetization solution to unify its IT infrastructure, enhance both consumer and enterprise offerings and accelerate the delivery of new digital services and experiences in support of its long-term growth strategy.

    By consolidating across its businesses with MATRIXX, StarHub will benefit from cloud native componentized architectures and simplified revenue operations. The unlimited configurability of its monetization rules and account relationships will enable the rapid deployment of innovative 5G services, driving new growth opportunities and delivering real-time digital experiences that its customers have come to expect.

    “Singapore has one of the most dynamic mobile markets in the world, boasting among the highest smartphone penetration rates globally,” said Tom Fisher, vice president of APAC sales at MATRIXX Software. “We are excited to continue our partnership with StarHub, delivering the agile, real-time charging capabilities that enable them to bring new digital products and services to market faster and deliver world-class customer experiences.”

    To learn more about MATRIXX and StarHub, visit https://www.matrixx.com/customers/starhub/.

    About StarHub

    StarHub is a leading homegrown Singapore company that delivers world-class communications, entertainment, and digital services. With our extensive fibre and wireless infrastructure and global partnerships, we bring to people, homes and enterprises quality mobile and fixed services, a broad suite of premium content, and a diverse range of communication solutions. We develop and deliver solutions incorporating artificial intelligence, cybersecurity, data analytics, Internet of Things, and robotics for corporate and government clients.

    StarHub is committed to conducting our business sustainably and responsibly. StarHub is named among TIME’s World’s Most Sustainable Companies 2025 and ranked as the world’s most sustainable wireless telecommunication provider on the Corporate Knights Global 100 (2025). StarHub also ranks 187 on the FORTUNE Southeast Asia 500 in 2025. Listed on the Singapore Exchange mainboard, StarHub is a component stock of the SGX iEdge Singapore Low Carbon Index, iEdge-OCBC Singapore Low Carbon Select 50 Capped Index; as well as the FTSE4Good Index series.

    Visit www.starhub.com for more information.

    About MATRIXX Software
    MATRIXX Software delivers a dynamic billing, monetization and charging solution proven at scale. Global service providers like Telefónica, IoT providers like Tata Communications and network-as-a-service providers like DISH rely on MATRIXX to overcome the limitations of existing billing applications. MATRIXX provides a unified platform that transforms and simplifies billing operations across consumer, enterprise and wholesale businesses. With MATRIXX, operators can rapidly configure, deploy and monetize personalized offerings, enabling commercial innovation and real-time customer experiences that drive revenue and growth. 

    matrixx.com

    Media Contact
    mediainquiry@matrixx.com

    SOURCE: MATRIXX SOFTWARE

    View the original press release on ACCESS Newswire

    The post MATRIXX Software Extends Monetization Partnership With StarHub appeared first on DA80 Hub.

  • National Law Review and INSIDE Public Accounting Launch a New Monthly Newsletter

    National Law Review and INSIDE Public Accounting Launch a New Monthly Newsletter

    NLR x IPA Accounting News launched on July 23, bringing key accounting industry insights to its readers

    CHICAGO, IL / ACCESS Newswire / July 28, 2025 / The National Law Review (NLR) and INSIDE Public Accounting (IPA) are proud to announce the launch of NLR x IPA Accounting News, a new monthly newsletter designed to bring accounting news, insights and data directly to legal, tax, and accounting professionals, accounting-adjacent service providers, as well as to the private equity community. In particular, the newsletter will focus on structural changes to the accounting industry, such as firm mergers and the increasing prevalence of private equity investment in the sector.

    The newsletter will be available via the National Law Review’s Newsletters section on its website and through monthly email subscription. The newsletter will feature curated articles, timely industry data and insights from the accounting profession with crossover relevance to the legal and financial sectors.

    “This collaboration marks an exciting opportunity to expand the reach of our reporting and connect with a broader community of professionals,” said Chelsea Summers, Executive Director of INSIDE Public Accounting. “We’re looking forward to sharing timely, relevant content with a new audience that values high-quality insights into firm performance, leadership and strategy. It’s a natural alignment, and we believe this partnership will bring meaningful value to both accounting and legal professionals navigating an increasingly complex business landscape.”

    The partnership brings together NLR’s extensive reach in the legal sector and IPA’s long-standing reputation for authoritative accounting industry analysis. Both organizations recognize the growing alignment between legal and accounting firm objectives, particularly in areas such as firm leadership, operational strategy, mergers and acquisitions and overall practice management.

    NLR x IPA Accounting News builds on IPA’s existing research and analysis, serving it up in a new format tailored specifically for NLR’s professional readership and private equity investors.

    About INSIDE Public Accounting (IPA)

    INSIDE Public Accounting (IPA) has been delivering benchmarking reports, practice management resources, and editorial insight to the public accounting profession for 35 years. IPA is known for its annual rankings, in-depth firm performance data, and trusted voice on trends shaping the accounting profession. Learn more at insidepublicaccounting.com

    About The National Law Review (NLR)

    The National Law Review is a leading online platform for legal and business news and analysis, offering a curated selection of articles authored by attorneys and other thought leaders. With millions of monthly readers and a strong newsletter subscriber base, NLR provides valuable legal insights to business leaders, attorneys, investors, and those following the tax and accounting field. Visit natlawreview.com

    To Subscribe to NLR x IPA Accounting News – see: National Law Review’s Newsletters section

    Media Contact:
    Billy Thieme, Communications Director
    (708) 357-3317
    publicnotices@natlawreview.com

    SOURCE: The National Law Review

    View the original press release on ACCESS Newswire

    The post National Law Review and INSIDE Public Accounting Launch a New Monthly Newsletter appeared first on DA80 Hub.

  • Quarterly Activities and Cashflow Report

    Quarterly Activities and Cashflow Report

    ADELAIDE, AU / ACCESS Newswire / July 28, 2025 / Barton Gold Holdings Limited (ASX:BGD)(FRA:BGD3)(OTCQB:BGDFF) ( Barton or Company ) advises that the Quarterly Activities and Cashflow Report for the quarter ended 30 June 2025 has been released to the market.

    These reports can be accessed directly via the following links:

    Authorised by the Managing Director of Barton Gold Holdings Limited.

    For further information, please contact:

    Alexander Scanlon
    Managing Director
    a.scanlon@bartongold.com.au
    +61 425 226 649

    Jade Cook
    Company Secretary
    cosec@bartongold.com.au
    +61 8 9322 1587

    About Barton Gold

    Barton Gold is an ASX, OTCQB and Frankfurt Stock Exchange listed Australian gold developer targeting future gold production of 150,000ozpa with 2.1Moz Au & 3.1Moz Ag JORC Mineral Resources (78.9Mt @ 0.85 g/t Au), brownfield mines, and 100% ownership of the region’s only gold mill in the renowned Gawler Craton of South Australia.*

    Competent Persons Statement & Previously Reported Information

    The information in this announcement that relates to the historic Exploration Results and Mineral Resources as listed in the table below is based on, and fairly represents, information and supporting documentation prepared by the Competent Person whose name appears in the same row, who is an employee of or independent consultant to the Company and is a Member or Fellow of the Australasian Institute of Mining and Metallurgy ( AusIMM ), Australian Institute of Geoscientists ( AIG ) or a Recognised Professional Organisation (RPO). Each person named in the table below has sufficient experience which is relevant to the style of mineralisation and types of deposits under consideration and to the activity which he has undertaken to quality as a Competent Person as defined in the JORC Code 2012 ( JORC ).

    Activity

    Competent Person

    Membership

    Status

    Tarcoola Mineral Resource (Stockpiles)

    Dr Andrew Fowler (Consultant)

    AusIMM

    Member

    Tarcoola Mineral Resource (Perseverance Mine)

    Mr Ian Taylor (Consultant)

    AusIMM

    Fellow

    Tarcoola Exploration Results (until 15 Nov 2021)

    Mr Colin Skidmore (Consultant)

    AIG

    Member

    Tarcoola Exploration Results (after 15 Nov 2021)

    Mr Marc Twining (Employee)

    AusIMM

    Member

    Tunkillia Exploration Results (until 15 Nov 2021)

    Mr Colin Skidmore (Consultant)

    AIG

    Member

    Tunkillia Exploration Results (after 15 Nov 2021)

    Mr Marc Twining (Employee)

    AusIMM

    Member

    Tunkillia Mineral Resource

    Mr Ian Taylor (Consultant)

    AusIMM

    Fellow

    Challenger Mineral Resource

    Mr Ian Taylor (Consultant)

    AusIMM

    Fellow

    Wudinna Mineral Resource (Clarke Deposit)

    Ms Justine Tracey

    AusIMM

    Member

    Wudinna Mineral Resource (all other Deposits)

    Mrs Christine Standing

    AusIMM / AIG

    Member / Member

    The information relating to historic Exploration Results and Mineral Resources in this announcement is extracted from the Company’s Prospectus dated 14 May 2021 or as otherwise noted in this announcement, available from the Company’s website at www.bartongold.com.au or on the ASX website www.asx.com.au . The Company confirms that it is not aware of any new information or data that materially affects the Exploration Results and Mineral Resource information included in previous announcements and, in the case of estimates of Mineral Resources, that all material assumptions and technical parameters underpinning the estimates, and any production targets and forecast financial information derived from the production targets, continue to apply and have not materially changed. The Company confirms that the form and context in which the applicable Competent Persons’ findings are presented have not been materially modified from the previous announcements.

    Cautionary Statement Regarding Forward-Looking Information

    This document may contain forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “expect”, “target” and “intend” and statements than an event or result “may”, “will”, “should”, “would”, “could”, or “might” occur or be achieved and other similar expressions. Forward-looking information is subject to business, legal and economic risks and uncertainties and other factors that could cause actual results to differ materially from those contained in forward-looking statements. Such factors include, among other things, risks relating to property interests, the global economic climate, commodity prices, sovereign and legal risks, and environmental risks. Forward-looking statements are based upon estimates and opinions at the date the statements are made. Barton undertakes no obligation to update these forward-looking statements for events or circumstances that occur subsequent to such dates or to update or keep current any of the information contained herein. Any estimates or projections as to events that may occur in the future (including projections of revenue, expense, net income and performance) are based upon the best judgment of Barton from information available as of the date of this document. There is no guarantee that any of these estimates or projections will be achieved. Actual results will vary from the projections and such variations may be material. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. Any reliance placed by the reader on this document, or on any forward-looking statement contained in or referred to in this document will be solely at the readers own risk, and readers are cautioned not to place undue reliance on forward-looking statements due to the inherent uncertainty thereof.

    * Refer to Barton Prospectus dated 14 May 2021 and ASX announcement dated 25 July 2025. Total Barton JORC (2012) Mineral Resources include 1,049koz Au (39.7Mt @ 0.82 g/t Au) in Indicated category and 1,095koz Au (39.2Mt @ 0.87 g/t Au) in Inferred category, and 3,070koz Ag (34.5Mt @ 2.80 g/t Ag) in Inferred category as a subset of Tunkillia gold JORC (2012) Mineral Resources.

    SOURCE: Barton Gold Holdings Limited

    View the original press release on ACCESS Newswire

    The post Quarterly Activities and Cashflow Report appeared first on DA80 Hub.

  • Organto Foods Announces Appointment of Javier Reyes de la Campa as Co-Chair of the Board

    Organto Foods Announces Appointment of Javier Reyes de la Campa as Co-Chair of the Board

    VANCOUVER, BC AND BREDA, THE NETHERLANDS / ACCESS Newswire / July 28, 2025 / Organto Foods Incorporated (TSX-V:OGO)(OTC:OGOFF) (“Organto” or the “Company”) (“Organto” or the “Company”) is pleased to announce the appointment of Mr. Javier Reyes de la Campa as Co-Chair of the Board of Directors, alongside Steve Bromley, effective immediately.

    Javier Reyes de la Campa is a seasoned professional and entrepreneur with over 25 years of experience in investing and building companies. He has co-founded various firms across the finance, mining, agriculture and food sectors. More recently, his strategic leadership was instrumental in the strategic turnaround of Luca Mining Corporation, a producing company with assets in Mexico. Luca Mining Corporation was recently named to the 2025 Toronto Stock Exchange Venture 50™ list of top-performing companies. Mr. Reyes de la Campa was a founding director of Organto Foods and previously served on the Board of Directors from 2015 through 2020. An alumnus of Harvard Business School, Mr. Reyes de la Campa holds dual bachelor’s degrees in economics and business administration, as well as a master’s degree in finance from the Instituto Tecnológico Autónomo de México.

    Steve Bromley, Chief Executive Officer and Co-Chair of Organto Foods, commented: “We are thrilled to welcome Javier as Co-Chair. His strategic insight, leadership experience, and international perspective will be invaluable as we continue to grow our platform and meet the increasing global demand for organic and responsibly sourced food products. Javier joins us at an optimal time, as the we are accelerating our growth and profitability as well as widening our product offering.”

    Javier Reyes de la Campa, Co-Chairman, added: “I am honored and excited to join Organto’s Board of Directors at this exciting time for the Company. I admire the hard work of Steve and the entire team over the past eighteen months to reposition the Company for success. The Company’s mission to make healthy, organic foods more accessible and its dedication to sustainable business practices align closely with my own values. I look forward to working alongside the Board of Directors and management team to unlock the Company’s full potential and maximize shareholder value.”

    Grant of Stock Options and Restricted Share Units

    The Company also announces that it has granted 125,000 stock options to certain employees as per the terms of the Company’s Share Option Plan. The options were granted at an exercise price of $0.54 per share and have a term of five years. The options issued will vest 20% immediately and 20% on each anniversary thereafter. In addition, 1,000,000 restricted stock units were issued to certain directors of the Company as per the terms of the Company’s Restricted Share Unit Plan. The restricted share units have a term of 3 years and will vest one-third after one-year and one-third every six months thereafter.

    ON BEHALF OF THE BOARD

    Steve Bromley
    Co-Chair and CEO

    For more information, contact:
    Investor Relations
    John Rathwell, Senior Vice President, Corporate Development
    647 629 0018
    info@organto.com

    Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

    ABOUT ORGANTO

    Organto is a leading provider of branded, private label, and distributed organic and non-GMO fruit and vegetable products using a strategic asset-lighter business model to serve a growing socially responsible and health-conscious consumers. Organto’s business model is rooted in its commitment to sustainable business practices focused on environmental responsibility and a commitment to the communities where it operates, its people, and its shareholders.

    FORWARD LOOKING STATEMENTS

    This news release may include certain forward-looking information and statements, as defined by law, including without limitation, Canadian securities laws and the “safe harbor” provisions of the US Private Securities Litigation Reform Act (“forward-looking statements”). In particular, and without limitation, this news release contains forward-looking statements respecting the Company’s belief that Mr. Reyes de la Campa’s insight, leadership experience and international perspective will be invaluable as the Company grows its platform focused on meeting global demand for organic and responsibly sourced food products and the Company’s belief that Mr. Reyes de la Campa is joining at an optimal time as the Company is accelerating its growth and profitability and widening it product offering. Forward-looking statements are based on a number of assumptions that may prove to be incorrect, including, without limitation, the assumption that Mr. Reyes de la Campa joining the Board of Directors as Co-Chair is a positive development for the Company. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in forward-looking statements in this news release include, among others, uncertainty regarding the regulatory risks; risks related to market volatility and economic conditions; risks related to unforeseen delays; and risks that necessary financing will be unavailable when needed. For further information on these and other risks and uncertainties that may affect the Company’s business, see the “Risks and Uncertainties” and “Forward-Looking Statements” sections of the Company’s annual and interim management’s discussion and analysis filings with the Canadian securities regulators, which are available under the Company’s profile at www.sedarplus.ca. Except as required by law, Organto does not assume any obligation to release publicly any revisions to forward-looking statements contained in this news release to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

    SOURCE: Organto Foods, Inc.

    View the original press release on ACCESS Newswire

    The post Organto Foods Announces Appointment of Javier Reyes de la Campa as Co-Chair of the Board appeared first on DA80 Hub.

  • Bynn Intelligence Reinvents Document Fraud Detection with Groundbreaking Acquisition and Revolutionary AI Model

    Bynn Intelligence Reinvents Document Fraud Detection with Groundbreaking Acquisition and Revolutionary AI Model

    Jul. 28, 2025 / PRZen / SAN FRANCISCO — Bynn Intelligence, the undisputed leader in identity verification and document fraud detection, today announced the strategic acquisition of the Swedish pioneer Dokumentbedrägeri AB in an all-cash transaction. This significant acquisition includes the flagship product PDFChecker.com, a state-of-the-art platform renowned globally for its unprecedented accuracy in identifying fraudulent and forged documents.

    Dokumentbedrägeri AB has spent the past two years perfecting an unparalleled AI-driven document forensic model, combining advanced transformer architectures and segmented modeling. This technology, paired with sophisticated content analysis, has pioneered a completely new AI category known as SFTN (Segmented Forensic Transformer Network), delivering groundbreaking accuracy of 99.3%, rigorously validated on a massive dataset of over 30 million manipulated documents collected since 2003.

    “This technology represents a major leap forward in our industry,” stated Mikael Hedlöf, CEO of Bynn Intelligence, Inc. “It sets a new standard for accuracy and effectiveness in document fraud detection, significantly raising the bar for what’s achievable in forensic AI.”

    Following the acquisition in January 2025, Bynn Intelligence swiftly secured a partnership with NVIDIA, leveraging a massive cluster of 128 NVIDIA B200 GPUs to further enhance the SFTN model. The next-generation SFTN Promodel is slated for launch in July 2025, promising even higher accuracy, unparalleled forensic detail, and unprecedented real-time processing capabilities.

    “Bynn Intelligence has always set the pace in document fraud detection, but this innovation propels us light-years ahead,” remarked Bynn Intelligence CEO. “With the power of the Segmented Forensic Transformer Network and NVIDIA’s elite computing resources, we’ve placed fraudsters irreversibly behind—it’s game over.”

    This acquisition firmly solidifies Bynn Intelligence’s position at the forefront of document fraud detection and sets a new industry benchmark.

    About Bynn Intelligence

    Bynn Intelligence is the global leader in AI-powered document fraud detection solutions, trusted by millions worldwide. By seamlessly integrating AI innovation and security, Bynn Intelligence continues to redefine industry standards, ensuring trust, transparency, and unparalleled accuracy.

    Media Contact

    press@bynn.com
    +1 (650) 646-7485

    For further information, visit www.bynn.com or https://pdfchecker.com

    Press Release Distributed by PRLog

    Source: Bynn Intelligence, Inc

    Follow the full story here: https://przen.com/pr/33587658

    The post Bynn Intelligence Reinvents Document Fraud Detection with Groundbreaking Acquisition and Revolutionary AI Model appeared first on DA80 Hub.

  • LandGate® Releases Q2 2025 U.S. Data Center Development Summary

    LandGate® Releases Q2 2025 U.S. Data Center Development Summary

    Jul. 25, 2025 / PRZen / DENVER — LandGate® has released its Q2 2025 U.S. Data Center Development Summary, revealing continued momentum and growth in the data center sector amid surging demand for AI-powered computing. This report offers crucial insights for developers and investors seeking to understand the fast-evolving market landscape, major capital flows, and emerging energy strategies.

    Among the key highlights for Q2 2025:

    • U.S. data center activity surged, fueled by rapid adoption of AI workloads.
    • Installed capacity increased by 17.7% over the quarter.
    • Hyperscalers drove more than $300 billion in capital expenditures.
    • Estimated total energy consumption reached 224TWh.
    • Landmark policy changes, such as the “Big Beautiful Bill,” spurred new rural developments.
    • Regional standouts included Ohio, Georgia, and Texas for major new projects.
    • Operators embraced innovation with mixed-source microgrids and private wire energy deals.

    Click here to download the full white paper and learn more.

    About LandGate

    LandGate® is the leading provider of data solutions for site selection, origination, development, financing, and market analysis of U.S. energy and infrastructure projects: data centers, energy storage, EVs, solar, wind, carbon, natural gas, and CCS.

    Media Contact

    Jaime Gastelle H
    Sr. Director of Marketing at LandGate
    press@landgate.com

    Source: LandGate®

    Follow the full story here: https://przen.com/pr/33587470

    The post LandGate® Releases Q2 2025 U.S. Data Center Development Summary appeared first on DA80 Hub.

  • A New Era of Fashion Collaboration Begins: Introducing the Global Fashion Membership Platform

    A New Era of Fashion Collaboration Begins: Introducing the Global Fashion Membership Platform

    Connect with designers, factories, and fashion professionals worldwide. Grow your network, find partners, and unlock new business opportunities across the global fashion supply chain.

    Jul. 24, 2025 / PRZen / NEW YORK — Unlock Exclusive Opportunities in Fashion – Join the Global Fashion Membership Today

    The fashion industry is evolving, and so is the way we connect. Today marks the official launch of the Global Fashion Membership platform – a dynamic new space where designers, factories, and fashion professionals from around the world come together to collaborate, grow, and thrive.

    Whether you’re a factory looking for new clients, a designer sourcing reliable production partners, or a fashion innovator seeking global exposure, this platform is built for you. The Global Fashion Membership unlocks exclusive access to industry events, curated networking, business-building tools, and a growing international community dedicated to shaping the future of fashion.

    “We created this platform to bridge the gaps in the fashion industry,” says Jacki Easlick, founder of Global Fashion Membership. “It’s more than just a directory or a group—it’s a living network where real partnerships, deals, and growth happen every day.”

    Platform Benefits Include:

    • A curated global directory of vetted designers, manufacturers, and service providers
    • Access to private member-only virtual and in-person fashion events
    • Business matching tools to find the right collaborators
    • Insights, trends, and education to stay ahead of the curve
    • A supportive community that’s actively invested in each other’s success
    • 18,000 total members and growing

    Fashion is global—your network should be too. The Global Fashion Membership empowers professionals at every stage of the supply chain to connect smarter, work better, and grow faster.

    Join the movement and be part of the future of fashion.

    Sign up now at https://app.joinit.com/o/gfm/ and unlock your exclusive access.

    For media inquiries, interviews, or partnership opportunities, please contact:
    Jacki Easlick LLC
    info@jackieaslick.com

    Press Release Distributed by PRLog

    Source: Jacki Easlick LLC

    Follow the full story here: https://przen.com/pr/33587115

    The post A New Era of Fashion Collaboration Begins: Introducing the Global Fashion Membership Platform appeared first on DA80 Hub.

  • Thermon(R) Introduces Poseidon(TM) and Pontus(TM) Liquid Load Banks: Revolutionizing Data Center Commissioning and Validation

    Thermon(R) Introduces Poseidon(TM) and Pontus(TM) Liquid Load Banks: Revolutionizing Data Center Commissioning and Validation

    AUSTIN, TX / ACCESS Newswire / July 29, 2025 / Thermon Group Holdings, Inc. (NYSE:THR) (“Thermon”), a global leader in thermal management, power distribution, and environmental controls, today announced its universal availability of their new Poseidon™ Liquid Load Bank (for US markets) and Pontus™ Liquid Load Bank (for non-US markets). These advanced systems are designed to accurately simulate real-world thermal and electrical demand, providing mission critical component test validation for data centers and other High Performance Computing (HPC) environments.

    The new liquid load banks offer a built-for-purpose solution for the rigorous demands of data center commissioning and start up. They serve as essential test validation systems for critical HPC data center infrastructure, like Coolant Distribution Units, Uninterruptible Power Supplies and back-up power generators.

    Key features and benefits of the Poseidon and Pontus Load Banks include:

    • A built-for-purpose liquid-cooled load bank targeting the data center commissioning and start-up market, including Integrated Systems Testing.

    • Industry-leading performance, sizing, and weight, contributing to the lower total cost of ownership.

    • Engineered for data center testing applications – with integrated modern controls and monitoring in a standardized package for quick delivery.

    • Simple, easy controls and a comprehensive audible alarm system to indicate high temperature, low flow, and low water conditions.

    • Modular design with the ability to connect over 100 units in series to test the increasing IT loads in the industry.

    Custom designed and optimized by process heating/heat transfer experts, but standardized for quicker lead times and more value, the Poseidon and Pontus Load Banks boast a robust capacity rating up to 600kW within a compact design. Built for rapid deployment, these lightweight systems feature a mobile, space-saving design, allowing for quick and efficient testing in different locations within modular, mobile HPC and other data center environments.

    Poseidon and Pontus load banks provide real-time oversight of the dynamic thermal performance and electrical demands crucial for a modern data center in the rapidly expanding age of artificial intelligence (AI).

    “The launch of the Poseidon and Pontus Liquid Load Banks marks a significant milestone for Thermon – greatly expanding our opportunity within the rapidly growing data center market.” said Bruce Thames, President & CEO of Thermon. “As data centers evolve to meet the intense demands of AI and HPC, the need for precise, reliable, and efficient validation tools is paramount. Our new liquid load banks deliver unparalleled performance, mobility, and ease of use, reinforcing Thermon’s commitment to providing innovative solutions that empower our customers to build and operate the most robust and efficient critical infrastructure.”

    The new liquid load banks are available globally and are certified to local requirements along with the following applicable standards: UL, CSA, CE, ASME, ANSI, NEMA, PED and NEC, ensuring compliance and reliability across diverse markets.

    For more information on the Poseidon and Pontus load banks, click here.

    Through its global network, Thermon provides safe, reliable and mission critical industrial process heating solutions. Thermon specializes in providing complete flow assurance, process heating, temperature maintenance, freeze protection and environmental monitoring solutions. Thermon is headquartered in Austin, Texas. For more information, please visit www.thermon.com.

    CONTACT:
    Michelle Saab,
    Senior Manager, Global Marketing
    Phone: +1-512-560-5482

    SOURCE: Thermon Group Holdings Inc.

    View the original press release on ACCESS Newswire

    The post Thermon(R) Introduces Poseidon(TM) and Pontus(TM) Liquid Load Banks: Revolutionizing Data Center Commissioning and Validation appeared first on DA80 Hub.

  • MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain

    MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain

    Oral, non-opioid drug candidate advancing through Phase 1 and nearing completion of the single ascending dose (SAD) portion as the Company prepares to launch U.S. Phase 2a by year-end

    MIAMI, FLORIDA / ACCESS Newswire / July 29, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company developing novel therapies for neurologic, neuropsychiatric, and metabolic disorders, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for Ketamir-2, a novel oral NMDA receptor antagonist for the treatment of neuropathic pain.

    The IND submission included a comprehensive data package encompassing preclinical pharmacology, safety, and toxicology studies, including a pivotal neurotoxicity study in Sprague-Dawley rats which showed no evidence of brain lesions or adverse CNS effects-a key distinction from traditional ketamine, which has been associated with NMDA-linked neurotoxicity and the formation of Olney lesions in similar preclinical models. These findings were reinforced by multiple validated neuropathic pain models-including chemotherapy-induced, diabetic, and nerve ligation-induced neuropathy-where Ketamir-2 consistently demonstrated potent analgesic effects and superior efficacy to gabapentin and pregabalin, with reversal of pain sensitivity observed in select models. The IND also incorporated the Company’s Phase 1 readiness data and manufacturing documentation.

    MIRA is nearing completion of the Single Ascending Dose (SAD) portion of its international Phase 1 trial at Hadassah Medical Center in Jerusalem, with dose escalation progressing smoothly. The Company is now preparing to initiate the Multiple Ascending Dose (MAD) portion of the study, which will assess the safety, tolerability, and pharmacokinetics of repeated dosing over several days. These data will help inform optimal dosing strategies as MIRA moves toward a Phase 2a study, with the goal of initiating its first U.S.-based efficacy trial in Q4 2025.

    “This IND approval validates the strength of our preclinical data and the differentiated pharmacology of Ketamir-2,” said Erez Aminov, Chairman and CEO of MIRA. “We are executing and advancing with precision and speed, and we believe Ketamir-2 may represent one of the most promising non-opioid, non-controlled neuropathic pain treatments in development today.”

    Building on Strong Preclinical Evidence

    Ketamir-2 has consistently demonstrated robust efficacy and safety across a range of preclinical studies:

    • In a chemotherapy-induced neuropathy model, Ketamir-2 achieved near-complete normalization of pain sensitivity and outperformed gabapentin by 60%

    • In a validated diabetic neuropathy model induced by a high-fat diet and low-dose streptozotocin (STZ) in rats, Ketamir-2 significantly reduced pain sensitivity, with some animals returning to pre-diabetic baseline sensitivity

    • In head-to-head studies using the chronic constriction injury (CCI) model-a widely accepted sciatic nerve ligation model of neuropathic pain-in rats, Ketamir-2 delivered up to 112% greater pain relief than pregabalin and 70% more than gabapentin

    • No hyperlocomotion, sedation, or behavioral disturbances were observed, even at high doses

    • A comprehensive neurotoxicity study confirmed absence of Olney lesions, a key safety concern in NMDA modulators like ketamine

    • Ketamir-2 was shown to cross the blood-brain barrier efficiently, supported by its non-P-gp substrate status and evidence of CNS penetration in preclinical models, supporting oral CNS activity. Preclinical data indicate Ketamir-2 achieves good oral bioavailability-significantly higher than traditional ketamine, which has very low bioavailability when taken orally. This advantage, along with its selective receptor targeting and long-acting metabolite Nor-Ketamir-2, supports its potential as an at-home treatment option.

    • Demonstrated antidepressant and anxiolytic-like effects in validated behavioral models, with no dissociative or psychotomimetic side effects

    Select findings were recently published in Frontiers in Pharmacology, confirming the molecule’s clean pharmacological profile and positioning Ketamir-2 as a differentiated and scalable alternative to existing treatments. Additional preclinical publications are in progress.

    Phase 2a Pathway and Strategic Expansion

    With IND clearance secured, MIRA plans to initiate a U.S.-based Phase 2a clinical trial in neuropathic pain in Q4 2025. In parallel, the Company is:

    • In discussions with a leading U.S. institution to explore a dedicated trial in chemotherapy-induced peripheral neuropathy (CIPN)

    • Evaluating a Phase 2a study in diabetic peripheral neuropathy (DPN), a large, underserved indication with rising prevalence

    • Advancing formulation development for topical Ketamir-2 for localized pain applications

    Neuropathic Pain: A High-Impact Opportunity Across North America

    Neuropathic pain is a widespread and growing concern across North America, with prevalence expected to rise due to aging populations and increasing rates of diabetes and cancer-related treatments. Current therapies often provide only modest relief and are frequently associated with side effects such as sedation, dizziness, weight gain, and dependency risk, limiting their long-term use.

    In chemotherapy-induced peripheral neuropathy (CIPN), a significant proportion of patients undergoing treatment experience chronic pain symptoms. Meanwhile, access to IV ketamine remains limited to specialized clinics with long wait times, high cost, and logistical burdens. Ketamir-2’s oral, non-dissociative, and non-opioid profile may help overcome these barriers-offering a more accessible and scalable solution for patients in need.

    “Ketamir-2 has demonstrated consistent, potent efficacy across preclinical pain models with a clean safety profile and broad therapeutic potential. The IND approval is a testament to our scientific rigor and may pave the way for meaningful clinical translation,” said Dr. Itzchak Angel, Chief Scientific Advisor at MIRA.

    Other Corporate Updates

    MIRA also reports that the planned acquisition of SKNY Pharmaceuticals remains on track, with shareholder approval expected in Q3 2025. SKNY-1, the lead asset from SKNY Pharmaceuticals, is a next-generation oral therapy in development for obesity and smoking cessation. In a recent zebrafish model of obesity and craving, SKNY-1 demonstrated up to 30% weight loss, reversal of high-calorie and nicotine-seeking behavior, normalization of appetite hormones, and preservation of muscle mass. Additionally, SKNY-1 reversed anxiety-like behavior in a validated CB1 agonist-induced model, suggesting a favorable neuropsychiatric safety profile. Designed to avoid the psychiatric side effects linked to earlier CB1-targeting drugs and nicotine cessation agents, SKNY-1 could offer a differentiated, well-tolerated alternative to GLP-1s and other interventions. Meanwhile, MIRA-55, the Company’s oral cannabinoid analog, recently showed comparable efficacy to morphine in inflammatory pain models and is under evaluation for further development.

    “MIRA is executing at the highest level across all fronts,” added Mr. Aminov. “Ketamir-2’s clinical momentum, the SKNY-1 merger, and advancing MIRA-55 collectively reflect our commitment to delivering innovative, safe, and scalable therapies for patients with limited options. We’re extremely proud of the team’s performance, and we are just getting started.”

    About MIRA Pharmaceuticals, Inc.

    MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company’s pipeline includes oral drug candidates designed to address significant unmet medical needs in areas such as neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline.

    Cautionary Note Regarding Forward-Looking Statements

    This press release and the statements of MIRA’s management related thereto contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA’s current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA’s control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA’s potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA’s programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at www.sec.gov and on MIRA’s website at https://www.mirapharmaceuticals.com/investors/sec-filings. MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

    Contact:
    Helga Moya
    info@mirapharma.com
    (786) 432-9792

    SOURCE: MIRA Pharmaceuticals

    View the original press release on ACCESS Newswire

    The post MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain appeared first on DA80 Hub.